Skip to content

IPI-145

DRUG11 trials

Sponsors

SecuraBio, SCRI Development Innovations, LLC, M.D. Anderson Cancer Center, Dana-Farber Cancer Institute

Conditions

Chronic Lymphocytic LeukemiaHealthyHealthy VolunteersHepatic ImpairmentLeukemiaLymphomaNon-Hodgkin LymphomaRheumatoid Arthritis

Phase 1

IPI-145 Single Ascending, Multiple Ascending, Food Effect and Drug-Drug-Interaction Study
CompletedNCT01549106
SecuraBioHealthy Volunteers
Start: 2011-08-31End: 2012-02-29Updated: 2021-03-17
IPI-145 ADME and Absolute Bioavailability Study
CompletedNCT01836861
SecuraBioHealthy
Start: 2013-03-31End: 2013-05-31Updated: 2021-03-17
Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies
CompletedNCT01871675
SCRI Development Innovations, LLCChronic Lymphocytic Leukemia, Lymphoma, Non-Hodgkin Lymphoma +1
Start: 2013-05-31End: 2016-06-30Updated: 2016-07-11
Phase 1 Study in Healthy Subjects to Evaluate the Effect of IPI-145 on the Pharmacokinetics of Midazolam
CompletedNCT01925911
SecuraBioHealthy
Start: 2013-08-31End: 2013-10-31Updated: 2021-03-17
Phase 1 Study in Healthy Subjects to Evaluate the Effect of Rifampin on the Pharmacokinetics of IPI-145
CompletedNCT01947777
SecuraBioHealthy
Start: 2013-10-31End: 2013-12-31Updated: 2021-03-17
Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects
CompletedNCT02095587
SecuraBioHepatic Impairment
Start: 2014-03-31End: 2014-10-31Updated: 2021-03-17
A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL
Active, not recruitingNCT02158091
Dana-Farber Cancer InstituteChronic Lymphocytic Leukemia
Start: 2014-06-27End: 2026-07-01Updated: 2026-02-13
Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145
CompletedNCT02307461
SecuraBioHealthy
Start: 2014-11-30End: 2015-09-30Updated: 2021-03-17

Phase 2

Phase 3

Related Papers